Benjamin Enns1, Emanuel Krebs1, Kora DeBeck2, Kanna Hayashi3, M-J Milloy4, Lindsey Richardson5, Evan Wood4, Bohdan Nosyk6. 1. BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada. 2. BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada; School of Public Policy, Simon Fraser University, Vancouver, BC, Canada. 3. BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada; Faculty of Health Sciences, Simon Fraser University, Vancouver, BC, Canada. 4. BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada; Department of Medicine, Division of AIDS, University of British Columbia, Vancouver, BC, Canada. 5. BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada; Department of Sociology, University of British Columbia, Vancouver, BC, Canada. 6. BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada; Faculty of Health Sciences, Simon Fraser University, Vancouver, BC, Canada. Electronic address: bnosyk@cfenet.ubc.ca.
Abstract
BACKGROUND: Costs attributable to criminal activity are a major component of the economic burden of substance use disorders, yet there is a paucity of empirical evidence on this topic. Our aim was to estimate the costs of crime associated with different forms and intensities of stimulant use. METHODS: Retrospective cohort study, including individuals from three prospective cohorts in Vancouver, Canada, measured biannually (2011-2015), reporting stimulant use at baseline assessment. Monthly crime costs included policing, court, corrections, and criminal victimization (2016 CAD). We estimated monthly crime costs associated with mutually exclusive categories of crack, cocaine, methamphetamine, and polystimulant use, stratified by daily/non-daily use, relative to stimulant abstinence, as well as the independent effects of treatment (opioid agonist (OAT) and other addiction treatment). We used a two-part model, capturing the probability of criminal activity and costs of crime with generalized linear logistic and gamma regression models, respectively, controlling for age, gender, education, homelessness, mental health issues, employment, prior incarceration, alcohol and opioid use. RESULTS: The study sample included 1599 individuals (median age 39, 65.9% male) assessed over 5299 biannual interviews. Estimates of associated monthly crime costs ranged from $5449 [95% C.I.: $2180, $8719] for non-daily polystimulant use, to $8893 [$4196, $13,589] for daily polystimulant use. Cost differences between daily/non-daily use, injection/non-injection, and stimulant type were not statistically significant. Drug treatment was not associated with lower monthly crime costs in our sample. CONCLUSIONS: Substantial crime-related costs were associated with stimulant use, emphasizing the urgency for development and implementation of efficacious treatment regimens.
BACKGROUND: Costs attributable to criminal activity are a major component of the economic burden of substance use disorders, yet there is a paucity of empirical evidence on this topic. Our aim was to estimate the costs of crime associated with different forms and intensities of stimulant use. METHODS: Retrospective cohort study, including individuals from three prospective cohorts in Vancouver, Canada, measured biannually (2011-2015), reporting stimulant use at baseline assessment. Monthly crime costs included policing, court, corrections, and criminal victimization (2016 CAD). We estimated monthly crime costs associated with mutually exclusive categories of crack, cocaine, methamphetamine, and polystimulant use, stratified by daily/non-daily use, relative to stimulant abstinence, as well as the independent effects of treatment (opioid agonist (OAT) and other addiction treatment). We used a two-part model, capturing the probability of criminal activity and costs of crime with generalized linear logistic and gamma regression models, respectively, controlling for age, gender, education, homelessness, mental health issues, employment, prior incarceration, alcohol and opioid use. RESULTS: The study sample included 1599 individuals (median age 39, 65.9% male) assessed over 5299 biannual interviews. Estimates of associated monthly crime costs ranged from $5449 [95% C.I.: $2180, $8719] for non-daily polystimulant use, to $8893 [$4196, $13,589] for daily polystimulant use. Cost differences between daily/non-daily use, injection/non-injection, and stimulant type were not statistically significant. Drug treatment was not associated with lower monthly crime costs in our sample. CONCLUSIONS: Substantial crime-related costs were associated with stimulant use, emphasizing the urgency for development and implementation of efficacious treatment regimens.
Authors: Louisa Degenhardt; Amanda J Baxter; Yong Yi Lee; Wayne Hall; Grant E Sara; Nicole Johns; Abraham Flaxman; Harvey A Whiteford; Theo Vos Journal: Drug Alcohol Depend Date: 2014-01-27 Impact factor: 4.492
Authors: Lianping Ti; Lindsey Richardson; Kora DeBeck; Paul Nguyen; Julio Montaner; Evan Wood; Thomas Kerr Journal: Drug Alcohol Depend Date: 2014-05-17 Impact factor: 4.492
Authors: Steven Shoptaw; Cathy J Reback; James A Peck; Xiaowei Yang; Erin Rotheram-Fuller; Sherry Larkins; Rosemary C Veniegas; Thomas E Freese; Christopher Hucks-Ortiz Journal: Drug Alcohol Depend Date: 2004-11-28 Impact factor: 4.492
Authors: Bohdan Nosyk; Daphne P Guh; Nicholas J Bansback; Eugenia Oviedo-Joekes; Suzanne Brissette; David C Marsh; Evan Meikleham; Martin T Schechter; Aslam H Anis Journal: CMAJ Date: 2012-03-12 Impact factor: 8.262
Authors: Lindsey A Richardson; Cathy Long; Kora DeBeck; Paul Nguyen; M-J S Milloy; Evan Wood; Thomas H Kerr Journal: J Epidemiol Community Health Date: 2015-02-17 Impact factor: 3.710
Authors: Evan Wood; Thomas Kerr; Brandon D L Marshall; Kathy Li; Ruth Zhang; Robert S Hogg; P Richard Harrigan; Julio S G Montaner Journal: BMJ Date: 2009-04-30